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October 2016It may also improve patient drug compliance to
help control risk factors of cardiovascular disease. This
study was designed to evaluate the blood pressure–
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Clinical Therapeuticscombination of irbesartan-atorvastatin compared with
monotherapy by either agent over an 8-week treatment
period.
Methods: Patients with comorbid hypertension and
hypercholesterolemia were screened for this randomized,
double-blind, Phase III study. Eligible study patients were
randomly assigned to test groups receiving a combina-
tion of irbesartan 300 mg and atorvastatin 40 mg or 80
mg (IRB300 þ ATO40 and IRB300 þ ATO80). Com-
parator groups comprised monotherapy groups with
irbesartan 300 mg (IRB300) or atorvastatin 40 mg
(ATO40) or atorvastatin 80 mg (ATO80), or placebo.
Patients who were eligible at screening were subjected to
a 4- to 6-week washout period before commencing 8
weeks of therapy per their assigned group. The primary
efﬁcacy end points were percent change in LDL-C and
sitting diastolic blood pressure (DBP) levels from baseline
to end of therapy. Tolerability proﬁles of combination
therapy were compared with other groups.
Findings: A total of 733 patients with comorbid
hypertension and hypercholesterolemia were screened
for this study; 230 eligible patients were randomized to
treatment. The mean age of patients was 58.9 (8.5)
years, and their mean body mass index was 25.8 (3.2)
kg/m2. More than two thirds (70.9%) of the study
patients were male. Mean LDL-C and sitting DBP levels
at baseline were 149.54 (29.19) mg/dL and 92.32 (6.03)
mm Hg, respectively. Percent reductions in LDL-C after
8 weeks were 46.74% (2.06%) in the IRB300 þ
ATO40 group and 48.98% (2.12%) in the IRB300 þ
ATO80 group; these values were 47.13% (3.21%) and
48.30% (2.98%) in the ATO40 and ATO80 compara-
tor groups. Similarly, a reduction in sitting DBP after 8
weeks was –8.50 (1.06) mm Hg in the IRB300 þ
ATO40 group and 10.66 (1.08) mm Hg in the IRB300
þ ATO80 group compared with 8.40 (1.65) mm Hg in
the IRB300 group. The incidence rate for treatment-
emergent adverse events was 22.27% and was similar
between the monotherapy and combination groups.
Implications: A once-daily combination product of
irbesartan and atorvastatin provided an effective, safe,
and more compliable treatment for patients with
coexisting hypertension and hyperlipidemia. Clinical-
Trials.gov identiﬁer: NCT01442987. (Clin Ther.
2016;38:2171–2184) & 2016 The Authors. Published
by Elsevier HS Journals, Inc.
Key words: atorvastatin, combination, hyperlipide-
mia, hypertension, irbesartan.2172INTRODUCTION
Hypertension and hyperlipidemia are 2 of the most
important risk factors in the development of cardio-
vascular disease, and they often coexist.1–3 These risk
factors act synergistically in disease progression, and
results from the Framingham Heart Study showed that
even a moderate increase in blood pressure (BP) and
cholesterol dysregulation has as much of a 10-year
congestive heart disease risk as marked elevation of
either factor alone.4 Recent guidelines for the
management of hypertension and hyperlipidemia, as
recommended by the Joint National Committee on
Prevention, Detection, Evaluation and Treatment of
High Blood Pressure 2014 (JNC VIII)5 and the
American College of Cardiology/American Heart
Association 2013 blood cholesterol guideline,6 res-
pectively, emphasize the overall assessment of BP and
serum lipid levels in evaluating cardiovascular risk
rather than assessment of each risk factor individually.7
Presently, the drugs with a preferred mechanism of
cardiovascular protection for antihypertensive therapy
are those that inhibit the renin-angiotensin system
(RAS).8 Two classes of the drugs (the angiotensin-
converting enzyme [ACE] inhibitors and the angiotensin
II receptor blockers [ARBs]) have been discovered to
have RAS inhibitory activity, albeit by different
mechanisms. Although ACE inhibitors hinder the
production of angiotensin II through the inhibition
of ACE, ARBs prevent the interaction of angiotensin II
with its receptor (AT1), which subsequently prevents
aldosterone secretion. However, ACE inhibitors may
also lead to the production of certain immunomodu-
latory peptides such as bradykinin and substance P,
which can result in dry cough and angioedema. In
contrast, ARBs, owing to their speciﬁcity for AT1,
provide sufﬁcient BP lowering without these side
effects.9–11
Many studies have shown a positive correlation
between blood cholesterol levels and cardiovascular
disease, and thus a reduction in cholesterol levels can
signiﬁcantly reduce the risk.12,13 Drugs belonging to
the hydroxymethylglutaryl coenzyme A reductase in-
hibitors (statins) are the most commonly prescribed
antihyperlipidemic agents. They act by inhibiting the
formation of mevalonate, the rate-limiting step in the
biosynthesis of cholesterol. Moreover, statins such as
atorvastatin also increase LDL receptors on hepato-
cytes, thereby enhancing its uptake from blood. The
latest, more potent statins such as atorvastatin can alsoVolume 38 Number 10
S.-H. Kim et al.effectively reduce plasma levels of LDL-C, total choles-
terol (TC), apolipoprotein B, VLDL-C, and triglycerides
(TG). Atorvastatin therapy has also led to a reduction in
the incidence of adverse cardiovascular events in pa-
tients with other risk factors in addition to dyslipidemia
such as hypertension14 and type 2 diabetes.15
Given the multifactorial nature of cardiovascular
disease, physicians have to rely on prescription of
multiple drugs to successfully manage the various
concomitant pathologies. The resulting polyphar-
macy, with numerous medications with varying regi-
mens, is one of the major reasons for nonadherence of
patients to their prescribed therapies and subsequent
failure in managing their disease.16 Hence, a patient-
friendly regimen, preferably with the least number of
doses that could be taken simultaneously, may have a
huge advantage in ensuring patient compliance. An
emerging concept of ﬁxed-dose combination (FDC)
therapy in whichZ2 drugs are combined into a single
dosage form aims at ensuring adherence to the
regimen by reducing the “pill burden” on the patients.
The safety and effectiveness, as well as improvement
in patient compliance, through the use of FDCs have
already been demonstrated.17,18 In clinical practice,
patients with cardiovascular risk factors such as
hypertension take antihypertensive agents as well as
lipid-lowering agents, and a co-prescription of irbe-
sartan and atorvastatin is already prevalent. Given the
pharmacokinetic proﬁle of both drugs, it is possible
for them to be administered once-daily. Thus, combin-
ing them into 1 formulation could improve patient
compliance with their medication.
We hypothesized that a combination of irbesartan
and atorvastatin would have excellent therapeutic
effect and an equivalent safety proﬁle compared with
either drug administered alone in patients with hyper-
tension and hyperlipidemia. To evaluate this theory,
these drugs were administered in 2 ﬁxed combinations
to eligible patients for an 8-week period; we then
compared the change in LDL-C and BP levels in these
patients versus those of study patients who received
single-agent therapy.PATIENTS AND METHODS
Study Design and Patient Recruitment
This randomized, double-blind, factorial, multi-
center, Phase III study was conducted in 22 study
centers throughout the Republic of Korea from JuneOctober 20162011 to February 2013. Eligible patients were aged
Z19 years and r75 years, provided informed
consent at screening, and presented with hypertension
and hyperlipidemia that could be categorized into
groups A, B, or C (in increasing order of disease
severity) based on BP and fasting serum lipid levels at
the randomization visit. The following describes
each group:
Group A: 0 to 1 cardiovascular risk factor or Z2
risk factors and 10-year risk o10%; BP, 140 r
systolic BP (SBP) o180 mm Hg and 90 r diastolic
BP (DBP) o110 mm Hg; fasting serum lipid, 130 r
LDL-C r 250 mg/dL; and TG o400 mg/dL.
Group B: Z2 cardiovascular risk factors and10-
year risk of 10% to 20%; BP, 140 r SBP o 180 mm
Hg and 90 r DBP o 110 mm Hg; fasting serum
lipid, 130 r LDL-C r 250 mg/dL; and TG
o400 mg/dL.
Group C: presence of coronary artery disease,
diabetes mellitus (glycosylated hemoglobin level
Z6.5% at visit 1) or other clinical manifestation of
atherosclerosis (eg, peripheral artery disease, abdomi-
nal aortic aneurysm, symptomatic carotid artery dis-
ease); 10-year risk 420%; BP, 130 r SBP o 160
mmHg and 80 r DBP o 100 mm Hg; fasting serum
lipid, 100 r LDL-C r 250 mg/dL; and TG,
o400 mg/dL.
Exclusion criteria were acute liver disease or hepatic
dysfunction (aspartate aminotransferase or alanine
aminotransferase levels Z2 times the upper limit of
normal), elevated serum creatinine level (Z2.5 mg/dL),
creatinine phosphokinase level 42 times the upper
limit of normal, elevated serum TG (Z500 mg/dL), a
history of an intervention using a stent in coronary
artery disease within the preceding 12 months, hyper-
sensitivity to a hydroxymethylglutaryl coenzyme A
reductase inhibitor, uncontrolled hypertension (SBP
Z180 mm Hg or DBP Z110 mm Hg with antihyper-
tensive medication measured at rest), uncontrolled
diabetes mellitus, currently taking any kind of lipid-
lowering drugs, diagnosed with myopathy, patients at
risk of myopathy (renal impairment or previous renal
dysfunction, hypothyroidism, genetic defects or family
history of myopathy, experienced previous muscle
toxicity with taking statins or ﬁbrates, prior liver
disease, or higher intakes of alcohol), participation
in other studies within 4 weeks before enrollment,
pregnant and breastfeeding women, women not using
adequate methods of contraception (women of2173
*Trademark: Aprovels (Handok Inc, Seoul, Republic of Korea)
†Trademark: Lipitors (Pﬁzer Korea Ltd, Seoul, Republic
of Korea)
Clinical Therapeuticschildbearing potential had to be using adequate meth-
ods of contraception), contraindicated medically or
mentally, forbidden legally, unable to participate in
clinical trial according to investigator’s decision, and
concomitant use of drugs that could possibly interact
with the study drugs.
The study period lasted 12 to 14 weeks and
included 4 patient visits: enrollment (screening), com-
mencement of treatment (baseline), and 2 follow-up
visits (4 and 8 weeks [4 days] after baseline). There
was a 4- to 6-week washout period between screening
and baseline, during which any antihypertensive or
antihyperlipidemic therapy the patient was receiving
before enrollment was stopped. In addition, patients
were provided nutritional counseling at the start of the
washout period to implement lifestyle changes and
patient education.
The study was conducted in accordance with the
Code of Ethics of the World Medical Association
(Declaration of Helsinki) for experiments involving
humans. The study protocol was approved by institu-
tional review boards at each participating center, and
all study participants provided written informed
consent.
Patient Data Collection
After checking for eligibility and after having
obtained informed consent, study patients were ques-
tioned about their demographic characteristics, life-
style habits, personal and familial medical history, and
concomitant medications. Patients also underwent a
physical examination, and vital signs (bp and heart
rate) were measured. Laboratory tests were conducted
to evaluate blood count, serum biochemistry (eg, TC,
HDL-C, TG, apolipoprotein A1 [apo A1], apolipo-
protein B [apo B]), urinalysis, glycosylated hemoglo-
bin, thyroid-stimulating hormone, and β-human
chorionic gonadotrophin (for pregnancy, where appli-
cable). These tests were repeated at each subsequent
visit (baseline and follow-up visits). Furthermore, data
on adverse events were collected from the baseline
visit onward. Data were also collected during follow-
up visits for medication compliance by evaluating the
number of unused tablets in the strips provided to the
patients.
Randomization and Study Treatments
Block randomization using the Proc plan procedure
of SAS software (SAS Institute, Inc, Cary, NC) was2174used by an independent randomization ofﬁcer for
assigning the patients to their treatment groups. An
arbitrarily selected block size was used for generation
of the randomization code in a ratio of 2:1:1 (for
co-administration:single agent:placebo). The study
cohort was divided into 6 groups: 2 assigned for
coadministration of 2 disparate combinations, 3
assigned to single-agent therapy, and 1 group receiving
placebo. The packaging ofﬁcer at the investigational
product formulation facility then packaged the study
drugs (or matching placebo) for each patient according
to the randomization code and delivered these to
the study pharmacist at each site before the start of
the study.
Study treatments comprised 2 test groups (irbesar-
tan 300 mg þ atorvastatin 40 mg [IRB300 þ ATO40]
and irbesartan 300 mg þ atorvastatin 80 mg [IRB300
þ ATO80]), 3 comparator single-agent groups (irbe-
sartan 300 mg [IRB300], atorvastatin 40 mg
[ATO40], and atorvastatin 80 mg [ATO80]), and 1
comparator placebo group (no active drug). As per the
regimen, patients received irbesartan 300 mg* (batch
H008 and AVFQ004) or atorvastatin 40 mg† (batch
1108080 and 0979111) or atorvastatin 80 mg† (batch
1021080 or 1161091). Matching placebos were
manufactured by Hanmi Pharmaceutical Co Ltd
(Seoul, Republic of Korea; batch P1101-1). In effect,
each patient, independent of the group he or she was
assigned to, consumed 3 tablets once daily: either a
combination of 2 drugs and 1 placebo, a single agent
and 2 placebos, or all placebos.Efficacy and Safety Assessment
Primary efﬁcacy end points were percent change
from baseline in LDL-C level and change from base-
line in mean sitting DBP level after the treatment
period of 8 weeks. Secondary efﬁcacy end points
assessed were percent change from baseline levels for
LDL-C and change from baseline in sitting DBP,
sitting SBP, TC, HDL-C, TG, apo A1, and apo B;
proportion of patients achieving LDL-C targets as
prescribed by the National Cholesterol Education
Program Adult Treatment Panel (NCEP ATP) III
guidelines; and/or bp targets as per JNC VII guidelines
between the coadministration and single-agent groupsVolume 38 Number 10
S.-H. Kim et al.at each follow-up visit (weeks 4 and 8). At screening,
bp was measured 3 times on both arms; the arm with
the higher mean sitting DBP was used for bp measure-
ments throughout the study (mean of triplicate read-
ings at each visit). A same model of mercury
sphygmomanometer (provided by the sponsor,
Hammi Pharmaceutical Co Ltd) was used at every
site for bp recordings, and if possible, the same
investigator measured the bp throughout the study.
Patients were advised to avoid caffeine, exercise, and
smoking for at least 30 minutes before bp measure-
ments. The blood lipid proﬁle (LDL-C, TC, TG, HDL-
C, apo A1, and apo B) was ascertained at local
laboratories at screening, and subsequent evaluations
were performed at a central facility (Samkwang
Medical Laboratories, Seoul, Republic of Korea) to
ensure uniformity.
Safety assessment parameters included the inci-
dence of adverse events (AEs), vital signs, laboratory
tests, physical examination, and ECG data. AEs were
described by using the Medical Dictionary for Regu-
latory Activities terminology and actual observations,
when the former was not possible. AEs were classiﬁed
as mild, moderate, or severe; their relationship to the
study and/or drug was based on the investigator’s
clinical judgment. Study investigators also recorded
any serious AEs and deaths and notiﬁed the corre-
sponding authorities.Statistical Analysis
According to the medical review of amlodipine/
atorvastatin ﬁxed combination (US Food and Drug
Administration new drug application 021540), ator-
vastatin lowered sitting DBP by 3.8 to 4 mmHg,
whereas irbesartan is known to cause less LDL-C
lowering. Sitting DBP was lowered by irbesartan 300
mg by 10.7 mm Hg. Taking a conservative approach
and assuming sitting DBP was lowered by irbesartan
300 mg by 10.5 mm Hg and by atorvastatin by 4 mm
Hg, the SD of the difference between the combination
product and the atorvastatin single agent was 7.03
mm Hg. With a test power of 80% (96% by 5 times
of β-adjustment), a 2-sided signiﬁcance level of 5%,
and a dropout rate of 10%, with a ratio of 2:1:1 (for
coadministration:single agent:placebo), a target of 230
patients was determined (25 patients each to be
included in the monotherapy and the placebo groups,
and 50 patients in the FDC group).October 2016End points of this study were tested at a 2-sided
signiﬁcance level of 5%. Categorical data were
analyzed by using the Cochran-Mantel-Haenszel test
for general association with groups A, B, and C
as stratiﬁcation variables. Continuous variables
were analyzed by using a 2  3 factorial ANCOVA
model with irbesartan, atorvastatin, irbesartan-by-
atorvastatin interaction terms, and baseline values as
covariates. Efﬁcacy analysis was performed with last-
observation-carried-forward applied only to missing
data in the study’s efﬁcacy end points or to subjects
who had at least 1 postbaseline efﬁcacy assessment.
For safety end points, raw data were analyzed because
they were without application of last-observation-
carried-forward. For continuous variables, means,
SDs, and minimum and maximum values were calcu-
lated for each treatment group, and 1-way ANOVA
was performed. For categorical variables, frequencies
and proportions were calculated, and Pearson’s χ2 test
or Fisher’s exact test was performed.
Primary efﬁcacy end points were the least squares
mean (LSM) of the percent change in LDL-C and
overall change in sitting DBP after 8 weeks of the
assigned regimen. Statistical hypothesis for the
primary efﬁcacy end point was tested in a “step-
down” process as depicted in Figure 1. Starting with
probing for statistical validity of overall drug effect,
it moved on to probe for individual drug effect and
individual combination effect. If the null hypothesis
at each step was rejected stepwise from step 1, the
hypothesis at the next step was tested. If the null
hypothesis could not be rejected, statistical testing for the
next step was not performed, and the result of
hypothesis testing at that step was considered to
indicate no statistically signiﬁcant difference. If, by
statistical analysis, the upper limit of the 95% two-
sided CI was o0 (or the P value was less than the
signiﬁcance level of 5%), superiority of coadministration
in mean LDL-C percent change and mean sitting DBP
change from baseline to entire treatment period (8
weeks) would be statistically proven.RESULTS
Patient Disposition, Demographic
Characteristics, and Baseline Variables
A total of 733 patients were screened for this study;
230 were randomized to treatment. Of these, 19
(8.3%) patients were withdrawn for various reasons,2175
Scteening patients
N = 733
n = 230
Randomized patients
PLA ATO40 ATO80 IRB300 IRB300+ATO40 IRB300+ATO80
n = 27
n = 25n = 26
NEE
FA set
n = 25
n = 2
n = 23
Withdrawal
Completion
n = 23
Completion
n = 28
Completion
n = 24
Completion
n = 56
n = 2
PD
n = 1n = 1
PD
n = 21
PP set
n = 22
PP set
PD
n = 2
n = 28 n = 24
PP set PP set
n = 54
PP set
n = 36
PP set
PD
Completion
n = 57
Completion
n = 2
Withdrawal
n = 1
Withdrawal
n = 1
Withdrawal
n = 5
Withdrawal
n = 1
Withdrawal
FA set
n = 25
FA set
n = 29
FA set
n = 25
FA set
n = 61
FA set
n = 58
n = 1
n = 31
NEE NEE
n = 3n = 2
n = 25 n = 61 n = 61
n = 1
n = 25 n = 31 n = 25 n = 61 n = 61
S/F: 251, TLC failure:252
n = 503
No medication
Safety set Safety set Safety set Safety set Safety set Safety set
Figure 1. Study flowchart. ATO ¼ atorvastatin; FA ¼ full analysis; IRB ¼ irbesartan; NEE ¼ no efficacy
evaluation; PD ¼ protocol deviation; PLA ¼ placebo; PP ¼ per protocol; S/F = screening failure;
TLC = therapeutic lifestyle change.
Clinical Therapeuticsincluding failure to meet eligibility requirements,
unacceptable bp levels, withdrawal of consent, and
physician judgment.
The mean age of the study patients was 58.9 (8.5)
years, and the cohort included mainly male subjects (n
¼ 158 [70.9%]) (Table I). The patients’ mean body
mass index was 25.8 (3.2) kg/m2, and 56.0% (n ¼
125) of the patients were current smokers or had
smoked in the past.
More than one half (n ¼ 131 [58.7%]) of the
patients were in group C based on their cardiovascu-
lar risk status. At baseline, mean LDL-C and sitting
DBP levels were 149.5 (29.2) mg/dL and 92.3 (6.0)
mm Hg, respectively. For the parameters of cardio-
vascular risk factor stratiﬁcation, serum lipid proﬁle,
and sitting DBP, there was no statistically signiﬁcant
difference between the treatment groups with the
exception of LDL-C level in group C (P ¼ 0.0239).
About two thirds (66.4% [n ¼ 148]) of the patients
presented with a medical history in addition to hyper-
tension and hyperlipidemia at the time of screening;
the most common disorders were metabolism and
nutrition related (48.9% [n ¼ 109]) followed by
cardiac disorders (6.3% [n ¼ 14]).2176More than three quarters (76.7% [n ¼ 171]) of
patients had previously been undergoing medical
therapy. The most commonly prescribed class of drugs
was lipid-modifying agents, prescribed in 108 (48.4%)
subjects, followed by agents acting on the
RAS (45.7% [n ¼ 102]). Antidiabetic agents were
the most commonly taken concomitant medication
during the course of study, reported in 117 (52.5%)
subjects.
Primary Efficacy Evaluation
The LSM of percent change in LDL-C from base-
line to the end of the study was –46.7% (2.1%) and
–49.0 (2.1%) in the IRB300 þ ATO40 group and the
IRB300 þ ATO80 group, respectively (Figure 2A).
These values were –47.1% (3.2%) in the ATO40
group and –48.3% (3.0%) in the ATO80 group. For
the antihyperlipidemic-null group, the LDL-C change
was –3.6% (3.2%) and 6.1% (3.2%) in the IRB300
and the placebo groups, respectively. Stepwise end
point analysis (Table II) revealed that atorvastatin,
alone or in combination with irbesartan, substantially
reduced LDL-C levels compared with the placebo or
irbesartan-only groups (P o 0.0001).Volume 38 Number 10
Table I. Patient demographic characteristics, risk stratification variables, and laboratory findings.
Variable PLA (n ¼ 25)
ATO40
(n ¼ 25)
ATO80
(n ¼ 29)
IRB300
(n ¼ 25)
IRB300 þ ATO40
(n ¼ 61)
IRB300 þ ATO80
(n ¼ 58) Total (N ¼ 223)
Age, y* 58.0 (6.9) 58.5 (10.4) 56.9 (7.8) 59.7 (9.3) 59.8 (8.3) 59.2 (8.5) 58.9 (8.5)
Sex, no. (%)
Female 10 (40.0) 4 (16.0) 10 (34.5) 2 (8.0) 24 (39.3) 15 (25.9) 65 (29.1)
Male 15 (60.0) 21 (84.0) 19 (65.5) 23 (92.0) 37 (60.7) 43 (74.1) 158 (70.9)
BMI, kg/m2* 26.0 (3.0) 26.0 (3.6) 25.8 (3.1) 27.4 (2.8) 25.2 (3.4) 25.6 (2.9) 25.8 (3.2)
Risk group, no. (%)
CV risk group A 5 (20.0) 4 (16.0) 4 (13.8) – 10 (16.4) 11 (19.0) 34 (15.3)
CV risk group B 5 (20.0) 7 (28.0) 7 (24.1) 9 (36.0) 12 (19.7) 18 (31.0) 58 (26.0)
CV risk group C 15 (60.0) 14 (56.0) 18 (62.1) 16 (64.0) 39 (63.9) 29 (50.0) 131 (58.7)
Sitting SBP, mm Hg* 145.7 (7.6) 148.7 (9.6) 143.6 (7.8) 145.4 (11.8) 144.5 (9.1) 146.0 (9.4) 145.5 (9.3)
Sitting DBP, mm Hg* 91.4 (5.2) 94.7 (6.0) 92.8 (6.9) 91.5 (6.1) 91.7 (5.9) 92.5 (6.0) 92.3 (6.0)
LDL-C, mg/dL* 148.4 (33.5) 151.7 (28.9) 152.4 (30.0) 145.5 (28.4) 154.5 (30.5) 144.2 (25.9) 149.5 (29.2)
TC, mg/dL* 224.0 (35.5) 223.6 (32.2) 233.6 (35.0) 216.8 (33.6) 231.2 (34.3) 221.0 (32.3) 225.6 (33.8)
HDL-C, mg/dL* 46.0 (8.6) 48.4 (10.4) 52.6 (11.6) 48.1 (9.2) 49.7 (9.7) 49.5 (10.3) 49.3 (10.1)
TG, mg/dL* 170.4 (55.5) 157.7 (8.4) 169.3 (82.1) 167.5 (70.8) 158.7 (67.0) 164.8 (77.8) 163.9 (69.1)
Apo A1, mg/dL* 139.1 (23.1) 140.0 (31.0) 149.9 (30.7) 139.9 (23.6) 141.9 (24.1) 142.6 (23.2) 142.2 (25.4)
Apo B, mg/dL* 134.0 (23.5) 135.5 (26.4) 138.5 (26.1) 131.9 (28.2) 139.4 (26.8) 130.8 (25.2) 135.2 (26.0)
Apo ¼ apolipoprotein; ATO ¼ atorvastatin; BMI ¼ body mass index; DBP ¼ diastolic blood pressure; IRB ¼ irbesartan; PLA ¼ placebo; SBP ¼ systolic blood
pressure; TC ¼ total cholesterol; TG ¼ triglycerides.
*Mean (SD).
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Figure 2. Change in (A) LDL-C (least squares
[LS] mean percent change) and (B)
sitting diastolic blood pressure (DBP)
(least squares mean change) from base-
line to week 8. ATO ¼ atorvastatin; IRB
¼ irbesartan; PLA ¼ placebo.
Clinical TherapeuticsSimilarly, the LSM of change in mean sitting DBP
by the end of the study was –8.50 (1.06) mm Hg and
–10.66 (1.08) mm Hg in the IRB300 þ ATO40 andTable II. Stepwise end point analysis summary for levels
Null Hypothesis LS Mea
Step 1: No overall effect of atorvastatin –
Step 2: No individual atorvastatin effect
ATO40 vs ATO not treated –
ATO80 vs ATO not treated –
Step 3: No atorvastatin combination effect
ATO40 þ IRB300 vs IRB300 –
ATO80 þ IRB300 vs IRB300 –
ATO ¼ atorvastatin; IRB ¼ irbesartan; LS ¼ least squares.
2178the IRB300 þ ATO80 groups, respectively, compared
with –8.40 (1.65) mm Hg in the IRB300 group
(Figure 2B). The sitting DBP reductions in the other
groups were –3.82 (1.66) mm Hg in the ATO40
group, –5.07 (1.53) mm Hg in the ATO80 group,
and –3.78 (1.65) mm Hg in the placebo group. The
reduction in sitting DBP in groups that received
irbesartan in combination was found to be
signiﬁcantly better than in those receiving
atorvastatin alone (IRB300 þ ATO40 vs ATO40,
P o 0.0186; IRB300 þ ATO80 vs ATO80,
P ¼ 0.0032), and the reduction in sitting SBP in the
irbesartan groups was also signiﬁcantly better than in
the atorvastatin groups (Table III).Secondary Efficacy Evaluation
By the end of study, the percent reduction in
LDL-C was slightly lesser in the groups receiving
atorvastatin in combination with irbesartan than in
groups receiving atorvastatin alone. However, this
difference was not statistically signiﬁcant (IRB300 þ
ATO40 vs ATO 40, P ¼ 0.9193; IRB300 þ ATO80
vs ATO 80, P ¼ 0.8537). Similarly, the changes in
other serum lipid factors (TC, HDL-C, TG, apo A1,
and apo B) were not statistically different between
groups receiving atorvastatin in combination or alone.
The antihypertensive effect of irbesartan in combina-
tion was also not potentiated/attenuated compared
with irbesartan alone.
The proportion of patients in the IRB300 þ
ATO40 group achieving their LDL-C target (accord-
ing to NCEP ATP III guidelines) after 8 weeks of
therapy was 86.9% (n ¼ 53) (Table IV). Inof LDL-C.
n Difference 95% CI P
42.93 –48.11 to –37.75 o0.0001
42.08 –47.94 to –36.23 o0.0001
43.78 –49.52 to –38.05 o0.0001
43.12 –50.66 to –35.59 o0.0001
45.36 –52.92 to 37.79 o0.0001
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Table III. Stepwise end point analysis summary for sitting levels of diastolic blood pressure (DBP) and systolic
blood pressure (SBP).
Null Hypothesis LS Mean Difference 95% CI P
Sitting DBP
Steps 1 and 2: No overall or individual effect of irbesartan
IRB treated vs IRB not treated –4.96 –7.32 to –2.61 o0.0001
Step 3: No irbesartan combination effect
IRB300 þ ATO40 vs ATO40 –4.68 –8.57 to –0.79 0.0186
IRB300 þ ATO80 vs ATO80 –5.59 –9.28 to –1.90 0.0032
Sitting SBP
Steps 1 and 2: No overall or individual effect of irbesartan
IRB treated vs IRB not treated –8.18 –13.5 to –2.86 0.0027
Step 3: No irbesartan combination effect
IRB300 þ ATO40 vs ATO40 –7.82 –13.94 to –1.71 0.0124
IRB300 þ ATO80 vs ATO80 –8.67 –14.49 to –2.84 0.0037
ATO ¼ atorvastatin; IRB ¼ irbesartan; LS ¼ least squares.
S.-H. Kim et al.comparison, this ﬁnding was 12.0% in the IRB300
group (P o 0.0001) and 92.0% in the ATO40 group
(P ¼ 0.5034). A higher proportion of patients in the
IRB300 þ ATO80 group (93.1% [n ¼ 54]) achieved
their LDL-C target by the end of the study compared
with the IRB300 (12.0%; P o 0.0001) and ATO80
(79.3%; P ¼ 0.0658) groups. Achievement of BPTable IV. Proportion of patients achieving LDL-C goal
Education Program Adult Treatment Panel III
Risk group
ATO40
(n ¼ 25)
ATO80
(n ¼ 29)
IRB3
(n ¼
Week 4
Group A 3 (75.0) 4 (100.0) 0
Group B 7 (100.0) 7 (100.0) 2 (22
Group C 13 (92.9) 15 (83.3) 1 (6
Overall 23 (92.0) 26 (89.7) 3 (12
Week 8
A 4 (100.0) 4 (100.0) 0
B 7 (100.0) 6 (85.7) 2 (22
C 12 (85.7) 13 (72.2) 1 (6
Overall 23 (92.0) 23 (79.3) 3 (12
ATO ¼ atorvastatin; IRB ¼ irbesartan.
October 2016targets (according to the JNC VII guidelines) was
not drastically different between the irbesartan þ
atorvastatin and irbesartan-alone groups either. The
proportion of patients achieving their BP targets at
week 8 was 48.0% (n ¼ 12) in the IRB300 group,
39.3% (n ¼ 24) in the IRB300 þ ATO40 group, and
55.2% (n ¼ 32) in the IRB300 þ ATO80 grouplevels as recommended by the National Cholesterol
guideline. Values are given as no. (%).
00
25)
IRB300 þ ATO40
(n ¼ 61)
IRB300 þ ATO80
(n ¼ 58)
9 (90.0) 11 (100.0)
.2) 11 (91.7) 16 (88.9)
.3) 32 (82.1) 27 (93.1)
.0) 52 (85.3) 54 (93.1)
9 (90.0) 11 (100.0)
.2) 11 (91.7) 15 (83.3)
.3) 33 (84.6) 28 (96.6)
.0) 53 (86.9) 54 (93.1)
2179
Table V. Proportion of patients achieving blood pressure targets recommended by the Joint National
Committee VII guideline. Values are given as no. (%).
Risk group
ATO40
(n ¼ 25)
ATO80
(n ¼ 29)
IRB300
(n ¼ 25)
IRB300 þ ATO40
(n ¼ 61)
IRB300 þ ATO80
(n ¼ 58)
Week 4
Group A 1 (25.0) 1 (25.0) 0 6 (60.0) 10 (90.9)
Group B 0 3 (42.9) 6 (66.7) 7 (58.3) 13 (72.2)
Group C 0 1 (5.6) 4 (25.0) 7 (18.0) 6 (20.7)
Overall 1 (4.0) 5 (17.2) 10 (40.0) 20 (32.8) 29 (50.0)
Week 8
A 1 (25.0) 2 (50.0) 0 7 (70.0) 9 (81.8)
B 2 (28.6) 3 (42.9) 8 (88.9) 7 (58.3) 14 (77.8)
C 2 (14.3) 4 (22.2) 4 (25.0) 10 (25.6) 9 (31.0)
Overall 5 (20.0) 9 (31.0) 12 (48.0) 24 (39.3) 32 (55.2)
ATO ¼ atorvastatin; IRB ¼ irbesartan.
Clinical Therapeutics(Table V). The proportion of patients who achieved
their LDL-C goal as well as their BP target by the end
of the study was higher in the coadministration groups
(34.4% [n ¼ 21] in the IRB300 þ ATO40 group and
50.0% [n ¼ 29] in the IRB300 þ ATO80 group). In
comparison, this ﬁnding was lesser in the single-agent
groups (data not shown).
Safety Evaluation
Treatment-emergent AEs (TEAEs) were reported in
51 (22.3%) patients (Table VI). These TEAEs were
mild (n ¼ 33) or moderate (n ¼ 18), and none was
severe. Most of the TEAEs were adjudged as unlikely
to be related to the study. Inexplicably, TEAE
incidence was the highest in the placebo group and
more or less similar in the treatment groups.
The incidence rate of adverse drug reaction was
4.4% (n ¼ 10). There were no serious adverse drug
reactions or deaths reported.
Medication Compliance
Overall mean medication compliance was 97.2%
(5.4%) and was Z96.0% in all treatment groups.DISCUSSION
Our study found that a combination of irbesartan 300
mg and atorvastatin 40 mg or atorvastatin 80 mg,2180once daily over a period of 8 weeks, was as efﬁcacious
as irbesartan alone as an antihypertensive agent and
atorvastatin alone as an antihyperlipidemic agent.
Moreover, this combination was more effective in
lowering sitting DBP and LDL-C than atorvastatin or
irbesartan monotherapy, respectively. The safety pro-
ﬁle of the irbesartan-atorvastatin combination was
comparable to that of monotherapy by either drug,
suggesting that the combination is acceptable for
clinical management of coexistent hypertension and
hyperlipidemia. In terms of achieving the prescribed
BP and LDL-C targets (as per JNC VII and NCEP
ATP III, respectively), the group receiving IRB300 þ
ATO80 had the highest incidence (55.2% for BP and
93.1% for LDL-C), although we found no statistical
signiﬁcance for this observation. Understandably, the
proportion of patients who achieved both targets was
highest in the combination groups (34.4% for IRB300
þ ATO40 and 50.0% for IRB300 þ ATO80). The
most important ﬁnding of our study was that a
combination of irbesartan and atorvastatin had no
effect on the individual therapeutic efﬁcacy of these
drugs as an antihypertensive and an antihyperlipi-
demic, respectively.
To gain the established beneﬁts of the current
paradigm (ie, a multifactorial approach to manage-
ment of cardiovascular risk factors), patient compli-
ance with prescribed therapeutic regimens is aVolume 38 Number 10
Table VI. Summary of adverse events. Values are given as no. (%).
Variable
PLA
(n ¼ 26)
ATO40
(n ¼ 25)
ATO80
(n ¼ 31)
IRB300
(n ¼ 25)
IRB300 þ ATO40
(n ¼ 61)
IRB300 þ ATO80
(n ¼ 61)
Total
(N ¼ 229)
Subjects with TEAEs 11 (42.3) 6 (24.0) 7 (22.6) 4 (16.0) 14 (23.0) 9 (14.8) 51 (22.3)
By severity
Mild 6 (23.1) 4 (16.0) 4 (12.9) 3 (12.0) 11 (8.0) 5 (8.2) 33 (14.4)
Moderate 5 (19.2) 2 (8.0) 3 (9.7) 1 (4.0) 3 (4.9) 4 (6.6) 18 (7.9)
Severe – – – – – – –
Relationship to IP
Deﬁnitely related – – – – – – –
Probably related 1 (3.9) - 1 (3.2) – 1 (1.6) – 3 (1.3)
Possibly related 1 (3.9) 1 (4.0) 1 (3.2) – 2 (3.3) – 5 (2.2)
Unlikely; probably not related 6 (23.1) 2 (8.0) 4 (12.9) 3 (12.0) 9 (14.8) 9 (14.8) 33 (14.4)
Deﬁnitely not related; none 3 (11.5) 1 (4.0) 1 (3.2) 1 (4.0) 2 (3.3) – 8 (3.5)
Unknown; could not be assessed – 2 (8.0) – – – – 2 (0.9)
ATO ¼ atorvastatin; IP ¼ investigational product; IRB ¼ irbesartan; PLA ¼ placebo; TEAE ¼ treatment-emergent adverse events.
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Clinical Therapeuticsprerequisite. This theory was illustrated by the obser-
vation that patients with higher compliance rates have
a signiﬁcantly lower risk of cardiovascular events
compared with those who are less compliant.19
However, 460% of patients with cardiovascular
disease are found to be nonadherent to their
prescribed medications, especially when multiple
drugs comprise the regimen.20,21
The concept of a combination pill containing lipid-
lowering drugs and an antihypertensive agent has
been studied since 2003, and various trials have
revealed promising results.22–26 However various is-
sues related to patents, drug interactions, regulatory
restrictions, and ﬁnancial aspects have to be addressed
before such FDC medications will be freely available
for clinical use.7 Given the usual coexistence of
hypertension and hyperlipidemia in cardiovascular
disease, designing an FDC that combines drugs that
lower BP as well as serum LDL-C offers a rational
approach to managing these risk factors. To this end,
one of the most tested combinations is that of
amlodipine, an antihypertensive that acts by blocking
calcium channels in the vascular smooth muscles, and
atorvastatin. Earlier studies such as Atorvastatin and
Amlodipine in patients with elevated lipids and
hypertension (AVALON)2 and efﬁcacy and safety
of ﬁxed-dose combinations of Amlodipine and
Atorvastatin in the treatment of patients with
concomitant hypertension and dyslipidemia
(RESPOND)3 evaluated co-administered amlodipine
and atorvastatin; since then, a single-pill combination
with these 2 agents has been shown to have an
acceptable efﬁcacy and safety proﬁle and help patients
achieve their BP and LDL-C targets and decrease their
absolute Framingham risk scores.18,27–30
In contrast, an ARB/statin combination has only
recently been assessed as an alternative in managing
hypertension and hyperlipidemia.31 Persistent or
postprandial hypertriglyceridemia and hyperglycemia
are known factors for endothelial damage and
dysfunction through oxidative stress, and they can
result in atherosclerosis.32,33 A combination of an
ARB and statins has been shown to decrease oxidative
stress, possibly due to an associated antioxidant
activity,34 thereby offering a promise of decreasing
endothelial damage, an independent cardiovascular
risk factor. Irbesartan has also been shown to reduce
microalbuminuria and have a renoprotective effect,35–37
which could offer additional beneﬁt in patients2182with diabetes (48.0% of the patients in our study
also presented with type 2 diabetes) who are at a
risk of diabetic nephropathy. In a previous study
assessing the pharmacokinetic properties and drug–
drug; unpublished study without reference; a previous
study assessing the pharmacodynamic properties and
drug–drug interactions.34
Despite the promising results of the present re-
search, it does have the inherent limitations of a Phase
III study. Study patients were carefully selected based
on eligibility criteria, and hence they cannot accurately
reﬂect a real-world scenario. The sample size was
small, which could be a signiﬁcant contributing factor
as to why we found no statistically signiﬁcant differ-
ences between the coadministration groups and ator-
vastatin alone for lowering LDL-C and irbesartan
alone as an antihypertensive agent. Moreover, with a
compliance rate Z96.0% in all groups, we could not
demonstrate an improvement in patient adherence to
the combination therapy of irbesartan and atorvasta-
tin, and we can only speculate that a combined single
pill with these 2 drugs would have better patient
acceptability. Compared with the chronic nature of
cardiovascular risk factors, our study was conducted
for only a period of 8 weeks, and it is therefore not
feasible to extrapolate the results for a longer
duration.CONCLUSIONS
Development of a once-daily combination product of
irbesartan and atorvastatin provided an effective, safe,
convenient, and patient-friendly treatment option for
coexistent hypertension and hyperlipidemia. More
long-term studies in various populations will be
required to validate the utility of this combination in
the real-world management of cardiovascular disease.CONFLICTS OF INTEREST
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